Soleno Therapeutics (SLNO) Stock Forecast, Price & News

Soleno Therapeutics (NASDAQ:SLNO) Frequently Asked Questions

Are investors shorting Soleno Therapeutics?

Soleno Therapeutics saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 283,400 shares, a decline of 25.5% from the April 15th total of 380,300 shares. Based on an average trading volume of 669,600 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.4% of the company's stock are sold short.
View Soleno Therapeutics' Short Interest.

When is Soleno Therapeutics' next earnings date?

Soleno Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Soleno Therapeutics.

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) posted its earnings results on Thursday, March, 31st. The company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08).
View Soleno Therapeutics' earnings history.

When did Soleno Therapeutics' stock split? How did Soleno Therapeutics' stock split work?

Soleno Therapeutics shares reverse split on Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.

Who are Soleno Therapeutics' key executives?

Soleno Therapeutics' management team includes the following people:

• Dr. Anish Bhatnagar, Pres, CEO, COO & Director (Age 52, Pay $756k)
• Mr. James H. MacKaness, Chief Financial Officer (Age 58, Pay $198.99k) (LinkedIn Profile)
• Mr. Anthony Wondka, Sr. VP & GM (Age 60)
• Dr. Neil M. Cowen M.B.A., Ph.D., MBA, Sr. VP of Drug Devel.

Who are some of Soleno Therapeutics' key competitors?

Some companies that are related to Soleno Therapeutics include IRIDEX (IRIX), BioSig Technologies (BSGM), Fc Global Realty (FCRE), electroCore (ECOR), Precision Optics (PEYE), Tivic Health Systems (TIVC), Positron (POSC), Vaso (VASO), Guided Therapeutics (GTHP), Star Equity (STRR), ENDRA Life Sciences (NDRA), Yubo International Biotech (YBGJ), Viveve Medical (VIVE), ADM Tronics Unlimited (ADMT) and Nuwellis (NUWE).
View all of SLNO's competitors.

What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD).

What is Soleno Therapeutics' stock symbol?

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

Who are Soleno Therapeutics' major shareholders?

Soleno Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Nantahala Capital Management LLC (11.78%), AIGH Capital Management LLC (8.49%), Granite Point Capital Management L.P. (3.30%), Worth Venture Partners LLC (2.11%), Empery Asset Management LP (1.75%) and Renaissance Technologies LLC (0.31%). Company insiders that own Soleno Therapeutics stock include Bhatnagar Anish, Jack W Schuler, James H Mackaness and William G Harris.
View institutional ownership trends for Soleno Therapeutics.

Which major investors are selling Soleno Therapeutics stock?

SLNO stock was sold by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, and Simplex Trading LLC. Company insiders that have sold Soleno Therapeutics company stock in the last year include Bhatnagar Anish, and Jack W Schuler.
View insider buying and selling activity for Soleno Therapeutics or view top insider-selling stocks.

Which major investors are buying Soleno Therapeutics stock?

SLNO stock was acquired by a variety of institutional investors in the last quarter, including AIGH Capital Management LLC, Granite Point Capital Management L.P., Worth Venture Partners LLC, Empery Asset Management LP, and Renaissance Technologies LLC. Company insiders that have bought Soleno Therapeutics stock in the last two years include Jack W Schuler, and James H Mackaness.
View insider buying and selling activity for Soleno Therapeutics or or view top insider-buying stocks.

How do I buy shares of Soleno Therapeutics?

Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Soleno Therapeutics' stock price today?

One share of SLNO stock can currently be purchased for approximately $0.20.

How much money does Soleno Therapeutics make?

Soleno Therapeutics has a market capitalization of $15.96 million. The company earns $-30.91 million in net income (profit) each year or ($0.350010) on an earnings per share basis.

How many employees does Soleno Therapeutics have?

Soleno Therapeutics employs 17 workers across the globe.

What is Soleno Therapeutics' official website?

The official website for Soleno Therapeutics is www.soleno.life.

How can I contact Soleno Therapeutics?

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The company can be reached via phone at (650) 213-8444, via email at [email protected], or via fax at 650-213-8383.